Market Overview:
The recombinant therapeutic protein market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for biologics, and technological advancements in the field of recombinant therapeutics. The recombinant human collagen segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the increasing use of recombinant human collagen in medical applications such as wound healing, tissue engineering, and cosmetic surgery. The North American region is expected to dominate the global recombinant therapeutic protein market during the forecast period.
Product Definition:
Recombinant therapeutic proteins are proteins that are produced through recombinant DNA technology. This technology involves the insertion of a gene into a host cell, which then produces the protein. Recombinant therapeutic proteins can be used to treat a variety of diseases, including cancer and HIV/AIDS. They are also being explored as potential treatments for other conditions, such as Alzheimer's disease and diabetes.
Recombinant Human Collage:
Recombinant human collage, also known as rhCollage or Recombinant Human Protein, is a protein that has been extensively studied due to its ability to bind specifically with itself in a cross-linked manner. This property makes it ideal for use in therapeutic protein formulations.
Recombinant Human Serum Albumin:
Recombinant human serum albumin is a protein that is produced by the fusion of human-globulin with bovine serum albumin. It has been used in therapeutic protein formulations for various diseases such as cancer, arthritis, etc. The recombinant proteins are manufactured using different techniques including genetic engineering and chemical synthesis to produce an identical molecule having the same three-dimensional structure as that of native human immunoglobulin.
Application Insights:
The other applications include the use of recombinant therapeutic proteins for research purposes and in nutraceuticals. The medicine segment dominated the global market with a share of over 60% in 2017. Increasing incidences of chronic diseases, such as diabetes, cancer, and cardiovascular diseases coupled with rising geriatric population across the globe is expected to drive demand for rTPA throughout the forecast period.
Rising adoption of advanced therapeutics techniques along with an increase in number of patients suffering from life-threatening conditions has led to increased usage recombinant Therapeutic Protein (rTPA) worldwide. This trend is expected to continue over the forecast period due to increasing awareness about advanced treatment options among consumers around the world especially after 2020 when more than 20 new clinical trials are scheduled by manufacturers every year which will further boost product demand globally during this timeframe.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of companies coupled with high R&D expenditure by the region is one of the major factors contributing to its growth. In addition, increasing government support for advanced therapeutics and growing focus on quality standards are also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising healthcare spending and improving economic conditions in emerging countries such as China and India.
In 2016, China accounted for majority share (58%) followed by U.S.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. According to a study by the World Health Organization (WHO), non-communicable diseases such as heart disease, stroke, cancer, and diabetes accounted for 63% of all deaths worldwide in 2012. This number is expected to rise to 73% by 2030. The growing incidence of chronic diseases will create a large demand for recombinant therapeutic proteins in the coming years.
- Technological advancements: The field of recombinant therapeutics is constantly evolving with new technological advancements being made every day. This has led to the development of novel protein therapies that are more effective and safer than traditional treatments options available today. Such advances are likely to fuel growth in the recombinant therapeutic protein market in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Therapeutic Protein Market Research Report
By Type
Recombinant Human Collage, Recombinant Human Serum Albumin
By Application
Medicine, Scientific Research, Others
By Companies
Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Eli Liily, GlaxoSmithKline, Merck, Novartis, Regeneron Pharmaceuticals, Roche, Takeda
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
162
Number of Tables & Figures
114
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Therapeutic Protein Market Report Segments:
The global Recombinant Therapeutic Protein market is segmented on the basis of:
Types
Recombinant Human Collage, Recombinant Human Serum Albumin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Medicine, Scientific Research, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celldex Therapeutics
- Eli Liily
- GlaxoSmithKline
- Merck
- Novartis
- Regeneron Pharmaceuticals
- Roche
- Takeda
Highlights of The Recombinant Therapeutic Protein Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Recombinant Human Collage
- Recombinant Human Serum Albumin
- By Application:
- Medicine
- Scientific Research
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Therapeutic Protein Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant therapeutic proteins are proteins that have been created through the use of recombinant DNA technology. This technology allows for the creation of new proteins that are not found in nature. These new proteins can be used to treat a variety of medical conditions.
Some of the key players operating in the recombinant therapeutic protein market are Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Eli Liily, GlaxoSmithKline, Merck, Novartis, Regeneron Pharmaceuticals, Roche, Takeda.
The recombinant therapeutic protein market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Therapeutic Protein Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Therapeutic Protein Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Therapeutic Protein Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Therapeutic Protein Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Therapeutic Protein Market Size & Forecast, 2018-2028
4.5.1 Recombinant Therapeutic Protein Market Size and Y-o-Y Growth
4.5.2 Recombinant Therapeutic Protein Market Absolute $ Opportunity
Chapter 5 Global Recombinant Therapeutic Protein Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant Therapeutic Protein Market Size Forecast by Type
5.2.1 Recombinant Human Collage
5.2.2 Recombinant Human Serum Albumin
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant Therapeutic Protein Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant Therapeutic Protein Market Size Forecast by Applications
6.2.1 Medicine
6.2.2 Scientific Research
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Therapeutic Protein Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Therapeutic Protein Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant Therapeutic Protein Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant Therapeutic Protein Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant Therapeutic Protein Market Size Forecast by Type
9.6.1 Recombinant Human Collage
9.6.2 Recombinant Human Serum Albumin
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant Therapeutic Protein Market Size Forecast by Applications
9.10.1 Medicine
9.10.2 Scientific Research
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant Therapeutic Protein Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant Therapeutic Protein Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant Therapeutic Protein Market Size Forecast by Type
10.6.1 Recombinant Human Collage
10.6.2 Recombinant Human Serum Albumin
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant Therapeutic Protein Market Size Forecast by Applications
10.10.1 Medicine
10.10.2 Scientific Research
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant Therapeutic Protein Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant Therapeutic Protein Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant Therapeutic Protein Market Size Forecast by Type
11.6.1 Recombinant Human Collage
11.6.2 Recombinant Human Serum Albumin
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant Therapeutic Protein Market Size Forecast by Applications
11.10.1 Medicine
11.10.2 Scientific Research
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant Therapeutic Protein Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant Therapeutic Protein Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant Therapeutic Protein Market Size Forecast by Type
12.6.1 Recombinant Human Collage
12.6.2 Recombinant Human Serum Albumin
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant Therapeutic Protein Market Size Forecast by Applications
12.10.1 Medicine
12.10.2 Scientific Research
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant Therapeutic Protein Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant Therapeutic Protein Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant Therapeutic Protein Market Size Forecast by Type
13.6.1 Recombinant Human Collage
13.6.2 Recombinant Human Serum Albumin
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant Therapeutic Protein Market Size Forecast by Applications
13.10.1 Medicine
13.10.2 Scientific Research
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Therapeutic Protein Market: Competitive Dashboard
14.2 Global Recombinant Therapeutic Protein Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Boehringer Ingelheim
14.3.2 Bristol-Myers Squibb
14.3.3 Celldex Therapeutics
14.3.4 Eli Liily
14.3.5 GlaxoSmithKline
14.3.6 Merck
14.3.7 Novartis
14.3.8 Regeneron Pharmaceuticals
14.3.9 Roche
14.3.10 Takeda
